Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Cytokinetics (CYTK) PT Raised to $110 at Barclays
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
